MedeliX
Start asking

Glimepiride

Glimepirid · ATC code A10BB12

Also known as: Glimepirid · Brand names: Amaryl, Glimepiride Abz, Glimepiride Denk, Magna, Diameprid, Glimax, Insuprid, Mepiriks, Tideca

Key facts
Active substance
Glimepiride
Drug class
Sulfonylurea
ATC code
A10BB12
Authorisation
authorised nationally; no central EU authorisation
Information as of
2026-10-29

Key facts

Glimepiride is, per the US prescribing information, a sulfonylurea used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

What it is used for

  • Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Not for type 1 diabetes or diabetic ketoacidosis.

Dosing

  • Take with breakfast or the first main meal of the day; starting dose 1 mg or 2 mg once daily.
  • Increased risk of hypoglycemia (e.g. elderly, renal impairment): start with 1 mg once daily and titrate conservatively.
  • From 2 mg daily, increase in steps of 1 mg or 2 mg based on glycemic response, no more often than every 1 to 2 weeks; maximum 8 mg once daily.
  • Switching from longer half-life sulfonylureas (e.g. chlorpropamide): overlapping effect possible for 1 to 2 weeks.
  • With colesevelam: take glimepiride at least 4 hours before.

Contraindications

  • Hypersensitivity to glimepiride or any of its ingredients.
  • History of allergic reaction to sulfonamide derivatives.

Important warnings

  • Hypoglycemia: all sulfonylureas can cause severe hypoglycemia, which may impair concentration and reaction (e.g. driving); warning symptoms may be blunted in autonomic neuropathy, the elderly or with beta-blockers.
  • Hypersensitivity reactions including anaphylaxis, angioedema and Stevens-Johnson syndrome; discontinue promptly if suspected.
  • Hemolytic anemia, particularly in G6PD deficiency.
  • Possible increased risk of cardiovascular mortality with sulfonylureas (UGDP study with tolbutamide).

Side effects

  • Most common in trials: hypoglycemia, dizziness, asthenia, headache and nausea.
  • In placebo-controlled trials included: headache 8.2%, accidental injury 5.8%, flu syndrome 5.4%, nausea 5.0%.
  • Postmarketing: impaired liver function up to liver failure, blood count changes, photosensitivity, hyponatremia/SIADH.

Interactions

  • Increased glucose lowering with, among others, other antidiabetics, insulin, ACE inhibitors, fluconazole, clarithromycin, quinolones, NSAIDs, salicylates and MAO inhibitors; monitor closely for hypoglycemia.
  • Reduced effect with, among others, danazol, glucagon, somatropin, protease inhibitors and atypical antipsychotics.
  • Colesevelam reduces glimepiride exposure.

Pregnancy and breastfeeding

  • Sulfonylureas cross the placenta; prolonged severe neonatal hypoglycemia has been reported, so stop at least two weeks before expected delivery.
  • Monitor breastfed infants for signs of hypoglycemia.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Patient information (US)

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

Austria

  • Glimepirid1a Pharma Gmbh, Teva B.V, Sandoz Gmbh, Hexal Pharma Gmbh · 4 register entries

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Germany

  • AmarylSanofi-Aventis Deutschland Gmbh · 1 register entry
  • Glimepirid1 A Pharma Gmbh, Ratiopharm Gmbh, Winthrop Arzneimittel Gmbh, Heumann Pharma Gmbh & Co. Generica Kg, Hexal Ag, Stadapharm Gmbh, Aliud Pharma Gmbh · 7 register entries
  • Glimepiride AbzAbz-Pharma Gmbh · 1 register entry
  • Glimepiride DenkDenk Pharma Gmbh & Co. Kg · 2 register entries
  • MagnaBerlin-Chemie Ag · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Turkey

  • AmarylSANOFİ SAĞLIK ÜRÜNLERİ LTD. ŞTİ. · 6 register entries
  • DiamepridPOLPHARMA SAĞLIK ÜRÜNLERİ SAN. VE TİC. A.Ş. · 7 register entries
  • GlimaxALİ RAİF İLAÇ SAN. A.Ş. · 7 register entries
  • InsupridWORLD MEDICINE İLAÇ SAN. VE TİC. A.Ş. · 4 register entries
  • MepiriksBİLİM İLAÇ SAN. VE TİC. A.Ş. · 6 register entries
  • TidecaSANOVEL İLAÇ SAN. VE TİC. A.Ş. · 12 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 25 more European countries
Belgium
Glimepiride Eg, Glimepiride Sandoz
Bulgaria
Амарил, Глимегамма Glimegamma, Инсуприд, Лимерал, Неоглим
Croatia
Amaryl, Melpamid
Cyprus
Amaryl, Dia-Ban, Sucryl
Czechia
Glimepirid Sandoz, Glimepirid Viatris, Oltar
Denmark
Glimepirid "sandoz", Glimepirid Bluefish, Glimepirid Stada
Estonia
Amaryl, Glimepiride Accord, Oltar
Finland
Oltar, Priglide
France
Amarel, Glimepiride Accord Healthcare, Glimepiride Arrow Generiques, Glimepiride Bgr, Glimepiride Cristers, Glimepiride Eg, Glimepiride Evolugen, Glimepiride Sandoz, Glimepiride Teva Sante, Glimepiride Viatris, Glimepiride Zentiva, Glimepiride Zydus
Greece
Anovis, Dia-Ban, Dialosa, Glidil, Glimerid, Gliperin, Mepirid, Solosa, Sucryl, Αdinsulin-S
Hungary
Glimepirid Hexal, Glimepirid Zentiva
Iceland
Glimeryl
Italy
Amaryl, Glimepiride Accord Healthcare, Glimepiride Aurobindo, Glimepiride Sandoz Gmbh, Solosa
Latvia
Amaryl
Lithuania
Amaryl
Luxembourg
Glimepiride Eg
Malta
Glimepiride Aurobindo
Netherlands
Amaryl, Fertin, Glimepiride Accord, Glimepiride Aurobindo, Glimepiride Cf, Glimepiride Sandoz, Glimepiride Zentiva
Norway
Glimepirid Teva
Poland
Amaryl, Diaril, Glibetic, Glimehexal, Glimepiryd Symphar, Symglic
Portugal
Glimepirida Aurovitas, Glimepirida Ciclum, Glimepirida Generis, Glimepirida Tolife, Glimial, Glimpor
Romania
Amaryl
Slovakia
Glimepirid Sandoz, Melyd, Oltar
Spain
Amaryl, Glimepirida Alter, Glimepirida Aurovitas, Glimepirida Cinfa, Glimepirida Kern Pharma, Glimepirida Normon, Glimepirida Pensa, Glimepirida Sandoz, Glimepirida Viatris, Roname
Sweden
Glimepirid Actavis, Glimepirid Bluefish, Glimepirid Stada

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Related calculators

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. U.S. Food and Drug Administration. Glimepiride (BluePoint Laboratories) – Prescribing Information, 2025-07-07. DailyMed (NLM), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a01b0466-13f5-4c47-ae55-c5f1527d9414
  2. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  5. Wikidata (CC0): ATC A10BB.

Editorial: Medelix editorial team · last updated 2026-10-29 · How these pages are made · Report an error

Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.